NSENews Verification14 Jul 2026 · 14 Jul 2026, 08:30 pm

News Verification

Zydus Lifesciences Limited · ZYDUSLIFE

✦ AI SummaryRegulatory

Zydus Lifesciences Limited has responded to a clarification sought by the National Stock Exchange of India Limited regarding a recent news item about a Delhi HC temporary restriction on the supply of its cancer drug Ikra due to an AbbVie patent dispute. The company stated that there are no negotiations or events requiring disclosure under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also claimed that the event is not material in terms of the company's materiality policy and the provisions of the regulations. The company's equity shares did not experience significant trading movement on July 14, 2026, and it believes there is no material impact of this event on the company.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is attached.

Attachments (1)

📄

Cadilahc_14072026203002_Replytostockexchanges14072026.pdf

pdf

Download →
View document text
July 14, 2026 Na(cid:415)onal Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Dear Sir / Madam, Re.: Clarifica(cid:415)on /Confirma(cid:415)on on news item appearing in “Media/Publica(cid:415)on” Ref.: Email of Na(cid:415)onal Stock Exchange of India Limited dated July 14, 2026 With reference to the cap(cid:415)oned email, we would like to inform as under that: a) there are no nego(cid:415)a(cid:415)ons or events which requires disclosure under regula(cid:415)on 30 of the SEBI (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015 (“the Lis(cid:415)ng Regula(cid:415)ons”). b) the said event (of passing of order by Hon’ble Delhi High Court to temporarily restrict the Company to supply of the cancer drug IkraTM) is not material in terms of the materiality policy of the Company and the provisions of the Lis(cid:415)ng Regula(cid:415)ons. c) due to the above news, there has been no material movement in the trading of equity shares of the Company on July 14, 2026. Further, we believe that there is no material impact of this event on the Company. The Company remains commi(cid:425)ed to complying with all applicable disclosure requirements under the Lis(cid:415)ng Regula(cid:415)ons and shall keep the stock exchanges informed of any material developments, if and when required. Please find our response in order. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063